back__Ari.jpg
 

 

Arietis is developing first-in-class small molecule antibiotics to kill drug resistant bacterial pathogens and treat infections with a high unmet clinical need.

 
 

 

info@arietiscorp.com

Copyright © 2018 Arietis Corporation - All Rights Reserved

 Courtesy of  Dr. Richard Lee

Courtesy of  Dr. Richard Lee

TECHNOLOGY

Imagine if antibiotics worked against complicated infections such as prosthetic joint infections, endocarditis, and osteomyelitis, and common infections were cured more quickly and effectively. 


This should be possible for the first time since Arietis is developing novel proprietary antibiotics that activate the ClpP protease and cause cells to self-digest. This unique “activating” mechanism causes rapid and exceptional killing of the highly resistant “ESKAPE” pathogens Staphylococcus aureus and Enterococcus faecium, as well as the leading cause of acute bacterial respiratory infections, Streptococcus pneumoniae.    


Killing by ClpP activation is effective against even non-growing cells, in contrast to other antibiotics, which target processes that are inactive in non-growing cells. Many bacteria can evade killing by traditional antibiotics, even surviving high concentrations for prolonged periods, by simply growing slowly or not at all. These survivors contribute to antibiotic resistance, cause recurrent infections, and explain why traditional antibiotics are unable to kill biofilms, which have restricted access to the immune system.  


However, bacteria cannot escape death by shutting down or waiting until antibiotic levels drop when ClpP is activated. Combining ClpP activators with traditional antibiotics prevented resistance development and caused eradication of MRSA infections in animal models where traditional antibiotics failed due to biofilms. This strategy may allow complicated infections to be cured with antibiotics for the first time and common infections to be treated more quickly and effectively with less recurrence.

 

It is important not to overlook the ongoing threat of antimicrobial resistance in Gram positive pathogens:

  • There are more deaths in the US from infections caused by drug resistant gram positive pathogens (MRSA, VRE and drug resistant S. pneumoniae) compared to the gram negatives (carbapenem-resistant Enterobacteriaceae, multidrug-resistant Pseudomonas and Acinetobacter).
  • There is still a high unmet need for novel antibiotics to treat drug resistant Gram positive infections especially for complicated infections such as endocarditis, osteomyelitis, diabetic ulcers, prosthetic joint and catheter related infections.

    

PUBLICATIONS

 

Conlon, B. P., E. S. Nakayasu, L. E. Fleck, M. D. LaFleur, V. M. Isabella, K. Coleman, S. N. Leonard, R. D. Smith, J. N. Adkins & K. Lewis, (2013) Activated ClpP kills persisters and eradicates a chronic biofilm infection. Nature 503: 365-370.

Gavrish, E., B. Shrestha, C. Chen, I. Lister, E. J. North, L. Yang, R. E. Lee, A. Han, B. Williams, D. Charnuska, K. Coleman, K. Lewis & M. D. LaFleur, (2014) In Vitro and In Vivo Activities of HPi1, a Selective Antimicrobial against Helicobacter pylori. Antimicrobial Agents and Chemotherapy 58: 3255-3260.

Michael LaFleur, Sun L., Keating J., Lister, I., Nantel A., Long L., Ghannoum M., North J., Lee R., Coleman K., Dahl T., Lewis K. (2013) Potentiation of Azole Antifungals by 2-adamantanamine. Antimicrob. Agents Chemother. 57(8):3585-92.

Lewis K. (2013) Platforms for antibiotic discovery. Nat Rev Drug Discov  12:371-387.

 

about arietis

 

Arietis is located at the Bio Square Discovery and Innovation Center on Boston University's Medical Campus.  Arietis was founded on technologies for discovering antimicrobials developed by Professor Kim Lewis at Northeastern University.  Dr. Michael LaFleur oversees daily laboratory operations. Following is a brief description of their backgrounds.

 

Kim Lewis, Ph.D.

Founder & Chairman of the Board

Dr. Lewis is a Professor of Biology and Director of the Antimicrobial Discovery Center at Northeastern University. He is an expert in microbial drug resistance and drug discovery. He received his Ph.D. in Biochemistry from Moscow University and prior to coming to NEU in 2001 has been on the Faculty of MIT, University of Maryland and Tufts University. Dr. Lewis is the author of over 100 publications, several patents and inventions licensed to the Industry.


MichaelLaFleur37.jpg

Michael LaFleur, Ph.D.

Chief Executive Officer

Dr. LaFleur is a co-inventor on key Arietis technology and has led operations for the past decade. Michael received his Ph.D. from Northeastern University, and has worked closely with Dr. Lewis to understand recalcitrant infections, and develop therapeutic approaches to make these infections treatable.

 

LOCATION

Arietis is located at 650 Albany St on the Boston University Medical School Campus. The parking garage is located at 710 Albany St.

 

Arietis

650 ALBANY ST

BOSTON, MA 02118

 

Parking

710 ALBANY ST
BOSTON, MA 02118

 
   Source

CONTACT US

If you would like further information about Arietis, please use this form to contact us:

Name *
Name